Andrea Alms Video:  Money In Motion 145 - Biotech IPO Market Forecast 2025

Andrea Alms Video: Money in Motion 145 - Biotech IPO Market Forecast 2025

TRANSCRIPT Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. Before we look at 2025, let's place it in context. Since 2014, the U.S. biotech IPO issuance still the proceeds and the number of IPOs have dropped more than 80% in 2023. It appears there has a notable change in the type of IPOs, with all ten companies having clinical trial assets and roughly a third having phase three assets.

It is a shift. The data suggest that it's a must have to be clinical stage to IPO. Please know the performance of the class of 2023 remains mixed because IPO, the life science IPO market, is off to a solid start in 2025. Various biotech companies have completed or launched their IPO so far in 2025. As of early February, five sizable life science companies have price their IPOs and one has filed to go public again after market performance of the price.

IPOs have been mixed so far. Here are the four pharma biotech IPOs that made it to Wall Street so far. Mette Sara, based in the US, is a clinical stage biotech company focused on delivering next gen peptide therapies for obesity, overweight and metabolic diseases. Maze Therapeutics, also headquarters in the US, is a clinical stage biopharmaceutical company focused on developing precision medicine for chronic kidney diseases, cardiovascular and metabolic conditions. Ascentage Pharma headquartered in China, the company specializes in discovering and developing innovative therapies for hematological normalizes, focusing on targeting key episodic pathways and tyrosine kinase. Zain Jain Biotech is based also in China, raised $6 million specializing in veterinary vaccines for livestock and companion animals, including swine, cattle and poultry. The company is expanding its portfolio to household animals.

Thank you. This is your money, your money, in motion.